Delamanid and pretomanid

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Pages2550-2558
Number of pages9
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
DOIs
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Delamanid and pretomanid'. Together they form a unique fingerprint.

  • Cite this

    Nuermberger, E., & Kendall, E. (2017). Delamanid and pretomanid. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2550-2558). CRC Press. https://doi.org/10.1201/9781315152110